<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230410057871N16</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-07-02</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>Comparing two surgical techniques for repairing flexor tendon injuries of the hand (Zone 1)</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of functional outcomes in Zone 1 flexor tendon injuries treated with classical transosseous versus paraosseous pull-out button techniques: A randomized, parallel-group, double-blinded (participant and outcome assessor) clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/91174</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization will be executed using a computer-generated random number sequence. Allocation concealment will be strictly maintained using sequentially numbered, opaque, sealed envelopes (SNOSE). Envelopes will be opened by a non-surgical staff member in the operating room just prior to the intervention to reveal the designated technique (A: Classical transosseous, B: Paraosseous), Blinding description: Due to the nature of the surgical intervention, the operating surgeon cannot be blinded. Therefore, this trial is double-blinded targeting the participants and the outcome assessors. Patients will be unaware of the specific button-placement technique used. Post-operative assessments (functional scoring, ROM, complications) will be conducted by an independent plastic surgeon who is entirely blinded to group allocation.</study_design>
      <phase>N/A</phase>
      <hc_freetext>ترمیم تاندون FDP، پارگی تاندون‌های فلکسور دست، آسیب‌های زون ۱ دست.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in this active control group will undergo Zone 1 FDP tendon repair utilizing the conventional pull-out method. Core sutures will be passed through drill holes created from the volar cortex extending through the dorsal aspect of the distal phalanx. The sutures will then be tied and secured over a button positioned directly on the nail plate. Intervention 2: Control group: Patients in this experimental intervention group will undergo FDP tendon repair via a paraosseous pull-out approach. To preserve the integrity of the nail bed and the distal phalanx bone, the sutures will be routed laterally through the paronychia (the soft tissue adjacent to the nail) without drilling the bone. The sutures are then secured to an externally placed button.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data set title: “Individual Participant Data (IPD) for the trial comparing FDP tendon repair by transosseous versus paraosseous pull-out methods.”

Data to be shared: All collected deidentified IPD underlying the results reported in the article, including primary and secondary outcome measures (VAS scores, chronic nail-bed pain, nail deformity, and range of motion/ROM), together with the data dictionary.

When:
Timing and Duration of Data Availability

The deidentified Individual Participant Data (IPD) and associated documentation for this study will become available six months after final publication of the manuscript in the target journal (expected in late 2026 or early 2027), through a reputable public repository (e.g., Figshare or Zenodo).

Duration of availability: The data will be retained and accessible for a minimum of five years from the date of publication.

Conditions of access: All applicants may request access by submitting a written request to the Principal Investigator and signing a Data Use Agreement, at no cost.

To whom:
Description of Persons and Institutions Eligible to Receive Deidentified IPD and Supporting Information

The deidentified Individual Participant Data (IPD) and accompanying supporting materials (including the data dictionary, analysis methodology, and statistical reports) will be made available to all researchers, scientists, and professionals in fields related to orthopedic surgery, hand surgery, microsurgery, and clinical sciences—regardless of whether they work in academic institutions, government agencies, industry, pharmaceutical companies, or medical technology firms.

Conditions and Requirements for Access:

Purpose of Use: Applicants must specify the intended purpose. Permitted uses include: academic research, medical product development, meta-analyses, health evaluations, and education.
Data Use Agreement (DUA): All applicants must sign a DUA committing to use the data solely for approved purposes.
Intellectual Property: The data remain the property of the original investigators. Applicants may not sell or redistribute the data.
Ownership of Results: Results derived from the data belong to the requesting researcher, provided that the original investigators are acknowledged as collaborators or sources in any final publication.
No Re-identification: Applicants must commit to not attempting to re-identify individuals from the deidentified dataset.
Oversight: The original investigators retain oversight rights and may revoke access in case of violation.
Notes:

Commercial use is permitted, subject to the above terms.
Uses that violate patient privacy or conflict with Iranian health and ethical regulations are prohibited.

Conditions:
Access Criteria and Data Sharing Mechanism

Types of analyses permitted:

Secondary analyses to address new research questions related to FDP tendon repair
Meta-analyses and systematic reviews
Validation studies and comparisons with similar datasets
Predictive modeling or advanced statistical analyses
Educational use in academic settings (with confidentiality safeguards)
Criteria for evaluating requests:

Scientific qualifications of the applicant: Documented research track record, publications, and relevant expertise
Clarity of research objective: Submission of a clear study protocol or research proposal
Scientific justification for data access: Demonstration of the necessity to access IPD
Adherence to ethical principles: Commitment to non-re-identification and privacy protection
No conflict of interest: Absence of commercial or competitive interests that compromise scientific integrity
Access mechanism:

Applicants must submit a written request to the Principal Investigator including:
Brief project description (maximum 500 words)
List of required data elements
Letter of introduction from affiliated institution
Academic CV
Request reviewers: Principal Investigator and the core research team
Review timeline: Maximum 4 weeks from receipt of complete application
Data delivery: Following approval and signing of the Data Use Agreement, data will be provided via secure download link or confidential repository
Reporting: Applicants must provide a summary of findings to the research team upon completion and properly cite the data source in any publications
Grounds for rejection:

Insufficient scientific justification
Clear conflict of interest or unauthorized commercial use
Failure to meet ethical or legal requirements

Where to obtain:
How to Access Data and Contact Information

To request access to the study data, applicants may contact the Principal Investigator through one of the following methods:

Principal Investigator:

[Full Name]

[Title and Institutional Affiliation]

Preferred method of communication: Email

Contact Information:

Email: [email address]
Telephone: [phone number with country code]
Fax: [fax number - if available]
Postal Address:[Department/Division][Institution/Hospital/University Name][Full Postal Address][City, Postal Code, Country]
Online Access:

Project Website: [URL - if available]
Data Repository: [Repository name and URL, e.g., Figshare, Zenodo, Dryad - if available]
Digital Object Identifier (DOI): [DOI for the dataset - if assigned]
Required Documentation for Request:

Completed application form (available via email)
Research protocol or study proposal
Applicant’s academic CV
Letter of introduction from affiliated institution
Signed draft Data Use Agreement
Response Time: Requests will be reviewed and responded to within 4 weeks.

How to obtain:
Step-by-Step Data Access Process and Estimated Timeline

Step 1 — Initial Contact and Form Request

The applicant emails the Principal Investigator to request the formal application form and the draft Data Use Agreement.

Estimated time: 1–3 business days to receive a response and the forms

Step 2 — Document Preparation by Applicant

The applicant prepares the research protocol, academic CV, institutional letter of introduction, and completed application form.

Estimated time: 1–2 weeks (depending on how quickly the institutional letter is obtained)

Step 3 — Submission of Complete Application

The full document set is submitted by email. The Principal Investigator confirms receipt.

Estimated time: 1–2 business days for acknowledgment

Step 4 — Scientific and Ethical Review

The Principal Investigator and core team evaluate scientific qualifications, research justification, and ethical compliance. Additional information may be requested.

Estimated time: up to 4 weeks from receipt of the complete application

Step 5 — Data Use Agreement Execution

Upon approval, the DUA is finalized and signed by both parties (and institutional legal/research offices if required).

Estimated time: 1–3 weeks (depending on the legal processes of both institutions)

Step 6 — Data Delivery

After the DUA is signed, data are provided via a secure download link or confidential repository.

Estimated time: 3–7 business days

Total approximate process time: about 8–12 weeks (from initial contact to data receipt)

Note: Factors affecting the timeline include the applicant’s speed in preparing documents, the need for institutional ethics committee review, and the complexity of DUA legal negotiations.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Arian Karimi Rouzbahani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Lorestan, Khorramabad, Moallem Street</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6813833946</zip>
        <telephone>+98 66 3326 6921</telephone>
        <email>ariankarimi1998@gmail.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Arian Karimi Rouzbahani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Lorestan, Khorramabad, Moallem Street</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6813833946</zip>
        <telephone>+98 66 3325 6921</telephone>
        <email>ariankarimi1998@gmail.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18 and 60 years.
Acute rupture or avulsion of the flexor digitorum profundus (FDP) tendon in Zone 1
Tendon gap/retraction of less than 1 cm
Time elapsed from initial injury is strictly less than 72 hours</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unwillingness to participate or anticipated non-compliance with the follow-up protocol.
Intra-articular fractures severely limiting baseline or potential range of motion.
Severe crush injuries or concomitant cartilaginous damage.
Current use of bone-depleting or immunosuppressive medications.
History of congenital/acquired bone defects or conditions impairing wound healing (e.g., uncontrolled diabetes mellitus, chronic infections, autoimmune disorders, HIV/AIDS).
Pregnancy.
History of keloid formation or inadequate soft tissue coverage at the surgical site.
Pre-existing conditions affecting the assessment of the contralateral digit (e.g., previous hand trauma, amputation, arthritis, congenital deformities, or baseline sensory impairments).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S66.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Injury of flexor muscle, fascia and tendon of other and unspecified finger at wrist and hand level</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in this active control group will undergo Zone 1 FDP tendon repair utilizing the conventional pull-out method. Core sutures will be passed through drill holes created from the volar cortex extending through the dorsal aspect of the distal phalanx. The sutures will then be tied and secured over a button positioned directly on the nail plate.</i_keyword>
      <i_keyword>Control group: Patients in this experimental intervention group will undergo FDP tendon repair via a paraosseous pull-out approach. To preserve the integrity of the nail bed and the distal phalanx bone, the sutures will be routed laterally through the paronychia (the soft tissue adjacent to the nail) without drilling the bone. The sutures are then secured to an externally placed button.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Functional disability and upper extremity functional outcome. Timepoint: At 6, 12, and 24 weeks post-operation. Method of measurement: Validated 30-item Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire.</prim_outcome>
      <prim_outcome>Range of motion of the Distal and Proximal Interphalangeal (DIP and PIP) joints. Timepoint: At 12 and 24 weeks post-operation. Method of measurement: Modified Strickland Score criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Grip and pinch strength (compared to the uninjured contralateral hand). Timepoint: At 12 and 24 weeks post-operation. Method of measurement: Jamar hydraulic hand dynamometer and Jamar hydraulic pinch gauge.</sec_outcome>
      <sec_outcome>Digit swelling/edema. Timepoint: At 3, 6, 12, and 24 weeks post-operation. Method of measurement: Measured via a finger circumference gauge (in millimeters) compared to the contralateral digit.</sec_outcome>
      <sec_outcome>Post-operative pain severity. Timepoint: At structured post-operative follow-up visits. Method of measurement: 10-point Visual Analogue Scale (VAS).</sec_outcome>
      <sec_outcome>Incidence of complications (nail bed deformity, chronic pain, wound infection, adhesion, tendon re-rupture). Timepoint: Monitored continuously up to 24 weeks post-operation. Method of measurement: Standardized clinical examination by a blinded assessor.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khoram-Abad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-06-02</approval_date>
        <contact_name>Ethics Committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>Moallem Street, Shahid Anushirvan Rezaei Square, University of Medical Sciences Khorramabad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
